Results 81 to 90 of about 6,491 (191)

GUIDELINES FOR THE USE OF SPECIFIC MONOCLONAL ANTIBODIES (PALIVIZUMAB) FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN SLOVENIA

Zdravniški Vestnik, 2002
Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in children under 12 months of age. Premature children and those with chronic lung disease are at increased risk for severe RSV infection.
Marko Pokorn, Milan Čižman, Janez Primožič, Janez Babnik, Silvo Kopriva, Zdravko Roškar   +5 more
doaj  

Respiratory syncytial virus infection and palivizumab: are families receiving accurate information

, 2012
The aim of this study was to assess the accuracy of information provided by medical practitioners to families regarding the efficacy and limitations of prophylaxis with palivizumab for respiratory syncytial virus (RSV) infection in infants.
Weiner, Joel H.
core   +1 more source

Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group

Pediatric Health, Medicine and Therapeutics, 2014
Gerard Notario,1 Pamela Vo,2 Katherine Gooch,2 Roger Deaton,3 Xionghua Wu,4 Brian Harris,4 Parthiv J Mahadevia,4 Pablo J Sánchez51Clinical Development and Medical Affairs, 2Global Heath Economics and Outcomes Research, 3Statistics, AbbVie Inc ...
Notario G, Vo P, Gooch K, Deaton R, Wu X, Harris B, Mahadevia PJ, Sánchez PJ   +7 more
doaj  

DISTRIBUTION PROFILE OF PALIVIZUMAB IN BRAZIL: ANALYSIS OF REGIONAL DISTRIBUTION BETWEEN 2014 AND 2024 FOR PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN CHILDREN CARED FOR BY THE UNIFIED HEALTH SYSTEM (SUS)

Brazilian Journal of Infectious Diseases
Introduction/Objectives: Palivizumab is recommended to prevent severe RSV infections in children at higher risk, such as preterm infants (gestational age ≤28 weeks) and children under 2 years of age with chronic lung disease or congenital heart disease ...
Jônatas Cunha Barbosa Lima, Daniel Moreira Alves da Silva, Luciana de Vasconcelos Rebouças, Kllysmann Santos Ribeiro, Thamela Cristiny Simão Alves, Vanessa Cristina Ribeiro, Matheus Malveira Vaz, Rodrigo Ramos Sena, Nara Amanda Laismann, Ana Liani Beisl Oliveira, Rafaela Tavares Peixoto, Luiz Henrique Costa, Marco Aurelio Pereira   +12 more
doaj   +1 more source

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

Jornal de Pediatria
Objective: This study aims to describe real world palivizumab use and effectiveness in high-risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received ...
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain   +5 more
doaj   +1 more source

Estudo de efectividade do Palivizumab [PDF]

, 2011
O Vírus Sincicial Respiratório (VSR) é o agente mais frequente das infecções respiratórias baixas nos primeiros dois anos de vida, sendo responsável por 50-90% dos episódios de bronquiolite nessa faixa etária.
Mira, Joana de Castela e
core  

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) hospitalizations have increased since the 2014 guideline update recommended against the use of palivizumab for preterm infants born ≥29 0/7 weeks' gestational age (GA) without additional risk factors. A novel
Tianzhou Yu, William V. Padula, Leah Yieh, Cynthia L. Gong   +3 more
doaj   +1 more source

Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is one of the major causes of respiratory tract infections among children. Until recently, the monoclonal antibody palivizumab was the only RSV prophylaxis available in Japan.
Naruhiko Ishiwada, Rina Akaishi, Yasuhiro Kobayashi, Kanae Togo, Naohiro Yonemoto, Moe Matsuo, Shinnosuke Kaneko, Amy W. Law, Kazumasa Kamei   +8 more
doaj   +1 more source

Palivizumab

medicina, 2002
D, Gupta, P, Gupta
openaire   +3 more sources

MODERN POTENTIALITIES OF IMMUNOPROPHYLAXIS OF SEVERE COURSE OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH THE CONSEQUENCES OF PERINATAL PATHOLOGY

Педиатрическая фармакология, 2011
To a risk group of a heavy course of the respiratory syncytial viral (RSV) infection could be ascribed preterm infants, born before the 35th week of gestation inclusive, as well as children under 2 years old with the bronchopulmonary dysplasia or ...
L.S. Namazova-Baranova, I.V. Davydova, T.V. Turti, I.A. Belyaeva, V.V. Altunin   +4 more
doaj